HRGN Stock Overview
A clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Harvard Apparatus Regenerative Technology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.45 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$2.13 |
| Beta | -1.42 |
| 1 Month Change | 5.60% |
| 3 Month Change | -34.32% |
| 1 Year Change | -58.19% |
| 3 Year Change | 85.61% |
| 5 Year Change | -17.51% |
| Change since IPO | -97.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| HRGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | 2.2% | 1.7% |
| 1Y | -58.2% | 5.8% | 26.0% |
Return vs Industry: HRGN underperformed the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: HRGN underperformed the US Market which returned 26% over the past year.
Price Volatility
| HRGN volatility | |
|---|---|
| HRGN Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HRGN's share price has been volatile over the past 3 months.
Volatility Over Time: HRGN's weekly volatility has increased from 16% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 18 | Jerry He | hregen.com |
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease.
Harvard Apparatus Regenerative Technology Inc. Fundamentals Summary
| HRGN fundamental statistics | |
|---|---|
| Market cap | US$32.92m |
| Earnings (TTM) | -US$8.08m |
| Revenue (TTM) | US$160.00k |
219.2x
P/S Ratio-4.3x
P/E RatioIs HRGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HRGN income statement (TTM) | |
|---|---|
| Revenue | US$160.00k |
| Cost of Revenue | US$36.00k |
| Gross Profit | US$124.00k |
| Other Expenses | US$8.21m |
| Earnings | -US$8.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 77.50% |
| Net Profit Margin | -5,051.25% |
| Debt/Equity Ratio | 285.7% |
How did HRGN perform over the long term?
See historical performance and comparison